1 / 6

BACE Inhibitors Pipeline to Witness Huge R&D Investment in the Coming Years

The study analysed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, in different stages of development.

NidhiNehani
Download Presentation

BACE Inhibitors Pipeline to Witness Huge R&D Investment in the Coming Years

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BACE Inhibitors Pipeline to Witness Huge R&D Investment in the Coming Years

  2. Beta-Secretase (BACE) Inhibitors Pipeline Analysis According to a new research report “Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, BACE inhibitors currently exhibit a pipeline with estimated 15 drug candidates. Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis BACE Inhibitors Exhibit an Emerging Pipeline with 10+ Drug Candidates The study analysed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, in different stages of development.

  3. Beta-Secretase (BACE) Inhibitors Pipeline Analysis Insights on pipeline segments As per the findings of the research, most of the pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route. Alzheimer’s disease drug development receives Fast Track designation Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company, received Fast Track designation by the U.S. Food and Drug Administration (FDA) in August 2016. The FDA’s Fast Track program was designed to expedite the development and review new therapies to treat serious conditions and tackle unmet medical needs.

  4. Beta-Secretase (BACE) Inhibitors Pipeline Analysis Major companies collaborate for the development of BACE inhibitors The research finds that different companies collaborated for the development of BACE inhibitors. Novartis entered in a global collaboration with Amgen to commercialize and develop BACE inhibitor program in September 2015 for Alzheimer's disease. Some of the key players developing BACE inhibitors are AstraZeneca plc, Eli Lilly & Company, Johnson & Johnson, and others.

  5. Beta-Secretase (BACE) Inhibitors Pipeline Analysis Download report sample at: https://www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related